EVO ICL › Is EVO ICL safe?
Is EVO ICL safe?
The three-year FDA trial numbers
The prospective multicenter FDA study followed 629 eyes of 327 subjects across 14 US clinical sites, with 92.1% completing the three-year visit. Mean postoperative uncorrected distance visual acuity was −0.053 logMAR, which is 20/20 or better. 48.9% of eyes gained one or more lines of best-corrected acuity, meaning they saw better after surgery than they previously could with glasses or contacts. The safety index was 1.25 at three years, anterior subcapsular cataract occurred in 0.16% of eyes, and there were no cases of pupillary block or pigment dispersion (PubMed).
The complication most within a surgeon's control
Sizing. Our review of exchanges and explants at a US high-volume center found that lens size, not the implant or the surgical technique, drives most of the reoperations that do occur (Clinical Ophthalmology, 2025). A lens that vaults too high or too low is a sizing decision made before the operation ever starts.
This is why the useful question for a prospective surgeon is not how many ICLs they have done, but how they choose the size: what imaging they use, whether they rely on a single white-to-white formula, and what their own exchange rate is. See how sizing is actually done.
I am a founding engineer of ICL Fit, the AI ICL-sizing agent grounded in the peer-reviewed VAULT and VAULT-OCT research and a large real-world dataset of EVO ICL surgical outcomes. The sizing decision above is the one it exists to get right.
The specific risks, one at a time
"Safe" is not a single number, and the individual risks behave quite differently from one another.
Cataract formation. The historical concern with phakic lenses, because an implant sitting close to the natural lens can interfere with the flow of nutrients across its surface. The EVO design addresses this with a central port that allows aqueous to circulate, and the three-year FDA data reflects it: anterior subcapsular cataract in 0.16% of 629 eyes. That is about one eye in six hundred. For everyday scale, that is roughly the odds of tossing a coin nine times and getting heads every single time. That is why we look at fit for each eye rather than a single vault number: a lens sitting too low sits closer to the natural lens than it should.
Raised intraocular pressure. Post-operative pressure spikes with the method we use have been very rare, and when they occur early they are typically transient and treatable. The three-year study reported no pupillary block, the mechanism that made older phakic lenses require a peripheral iridotomy.
Night vision symptoms. Halos and glare around lights, most noticeable in the first months and typically settling as the brain adapts. Larger pupils in dim conditions make them more likely. They are common enough that they should be discussed as an expected part of the early course rather than as a complication.
What "safety index 1.25" actually means
Safety index is the ratio of best-corrected visual acuity after surgery to best-corrected acuity before it. A value of 1.0 means the eye sees exactly as well as it did with its best glasses beforehand. 1.25 means it sees better.
That is counterintuitive until you consider what a strong spectacle lens does. Minifying a high myope's image, introducing distortion, and sitting a centimeter in front of the eye all degrade the retinal image in ways a lens inside the eye does not. The reason is the eye's nodal point, the spot the image is scaled around. How much a correcting lens shrinks or enlarges the picture depends on how far it sits from that point. A spectacle lens sits well in front of it, so for a myope it shrinks the retinal image. The ICL sits inside the eye, close to the nodal point, so the image lands on the retina at close to its natural size. Correcting the prescription without shrinking the picture is what lets best-corrected acuity go up. This is why 48.9% of eyes in the trial gained a line or more of best-corrected acuity, and it is the aspect of ICL that patients most consistently underestimate beforehand.
Related questions
Can an EVO ICL be removed? Yes. Reversibility is one of its defining advantages over corneal laser surgery. The lens can be removed or exchanged, most often because of sizing.
Does EVO ICL cause glaucoma? EVO ICL has a central port that allows fluid to flow without a peripheral iridotomy, and the three-year FDA study reported no cases of pupillary block or pigment dispersion. Angle anatomy is still assessed before surgery.
How does ICL safety compare with LASIK? Both have strong safety records in appropriate candidates. ICL avoids corneal tissue removal and the associated dry eye, while LASIK avoids an intraocular procedure. The comparison depends on your anatomy rather than on one being safer in general.
What is the most common EVO ICL complication? Cataract formation is the most discussed long-term concern, and in the three-year FDA trial anterior subcapsular cataract occurred in 0.16% of eyes. That is about one eye in six hundred. For everyday scale, that is roughly the odds of tossing a coin nine times and getting heads every single time. Elevated intraocular pressure and visual disturbances such as halos are the more common early issues.
Educational information, not medical advice. Discuss your specific eyes with a qualified ophthalmologist.